Resources

News

Alden Scientific Acquires Oncimmune Germany GmbH, Expanding Global Leadership in Multi-omic Research and Precision Medicine

Additional contract win with Top 10 Pharma Company

US $1.5m Contract Win with Top 10 Pharma Company

Investor Update

Oncimmune Announces Six Month Interim Results

Oncimmune Targets Age-Related Diseases with Biomarker Research.

Blog

Proust on Discovery: Why Alden Scientific Acquired Oncimmune GmbH

Autoantibodies in Neurology: Pioneering New Paths in Disease Detection and Treatment.

Redefining Microbiome Pathology through Autoantibody Biomarkers.

Advancing Precision Medicine: Insights from BIO2024

Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.

Video: Oncimmune Scientists Decode Autoantibody Reactome Using xMAP® Technology